Moderna likely to price Covid vaccine at $50-60 per course

Friday, 31 Jul, 2020

The cure is being developed by the Moscow-based Gamaleya Institute and once approved will be first given to frontline healthcare workers and then to the rest of the citizens.

"We are highly aware of our obligation during the pandemic phase to be responsible in how we price the vaccine", Bancel said.

"Russia will have got there first", Mr Dmitriev told CNN, likening the Russian coronavirus research to the successful launch of the world's first satellite by the Soviet Union in 1957. Americans were surprised when they heard Sputnik's beeping. "Russian Federation will have got there first", he added.

The phase III trial, dubbed the coronavirus efficacy (COVE) study, will test the vaccine in 30,000 participants at 100 research sites.

There are some concerns with this vaccine, since as per reports Russian Federation is still to complete their second phase and is already looking at launching the vaccine. "This vaccine is targeted agains those spikes". To introduce the vaccine, SII, the world's largest vaccine maker by number of doses produced and sold, has signed an agreement to manufacture the potential vaccine developed by the Jenner Institute (Oxford University) in collaboration with British-Swedish pharma company AstraZeneca. On Monday clinics around the U.S. began a Phase 3 trial of the vaccine candidate, with the aim of enrolling 30,000 people to test for safety and effectiveness. Fauci emphasised on rigorous trials and data safety monitoring boards in vaccine development.

Russian Federation has reported a total of 834,000 confirmed coronavirus cases, with 630,000 recoveries and 13,802 fatalities as of this week. The vaccine provided a robust immune response as demonstrated by "neutralizing antibodies", successfully preventing subsequent infection and providing complete or near-complete protection in the lungs from the virus in non-human primates, the company said. Volunteers receive either a vaccine or a placebo injected at two points 28 days apart.

The EU executive also said at the meeting that it had approached vaccine makers about whether additional doses of influenza vaccine were available, according to the document.

The study was funded by "Intramural Research Program of the Vaccine Research Center (VRC), NIAID, NIH, and the Office of the Assistant Secretary for Preparedness and Response, BARDA, Department of Health and Human Services (contract 75A50120C00034)".

The World Health Organization (WHO) has said that "this organism may be close wild-type and pathogenic, adapted and/or attenuated from wild-type with less or no pathogenicity, or genetically modified on some manner".

"(Regulatory) approval will be in the first two weeks of August", the development source said.

The first Phase 3 clinical trial for the coronavirus vaccine started in the United States on July 27.

Only the people handling the study will keep a record of who received which injections to later determine its effect on humans. Preparing manufacturing capacity for a potential vaccine entailed huge "financial" risk that the United States was willing to take, but the safety of study subjects would not be compromised, he added.